Psa Offer Payout: The Practical Version

how is the psa offer payout actually calculated?

A psa offer payout is calculated from the conversion event the advertiser is willing to buy: a paid sale, a qualified lead, a trial shipment, a continuity rebill, or a hybrid of those events. If your network says the offer pays $80, that number is not margin; it is the amount assigned to a tracked action after the advertiser, network, and risk controls have already shaped the terms.

The cleaner way to read the number is backward from the advertiser's unit economics. A $47 front-end supplement order that costs $4-$20 to make at stock private-label scale, per SMP Nutra's FAQ, still has to carry packaging, fulfillment, payment processing, refunds, support, reserves, and chargeback risk before anyone funds your affiliate commission. We counted those cost lines because the payout usually tells you less than the constraints around it.

The three payout rails

Most direct-response offers sit on 3 rails: CPA, cost per acquisition; CPL, cost per lead; and rev share, a percentage of collected revenue. CPA is easiest to buy against because you know the payable event. CPL can hide quality scoring, call-center acceptance, age filters, duplicate suppression, and geographic caps. Rev share can beat CPA only when your traffic produces clean rebills, low refunds, and enough attribution clarity that you can audit the ledger.

The number that matters is payable conversions per 1,000 clicks, not payout alone.

what eats the margin?

Manufacturing, fulfillment, compliance, chargebacks, reserves, and slow cash eat the margin before the buyer sees a stable payout. In supplements, the product cost swing alone is large: SMP Nutra publishes stock private-label supplements at $4-$20 per unit and custom formulas at $5-$30 per unit at its standard MOQ, minimum order quantity, of 2,500-5,000 bottles per SKU.

Format matters more than many media buyers price in. A 60-count bottle at around 5,000 units is listed at $2.50-$5.00 for capsules and tablets, $4.00-$8.00+ for gummies, and $5.00-$10.00 for liquids in Inventory Ready's cost table. That is why a gummy VSL with the same checkout price as a capsule offer can support a worse payout even when the funnel converts better.

Fulfillment is the second blunt object. Fulfyld publishes an average all-in fulfillment cost of $7.51 for a 4-12 oz package on standard 2-5 day shipping, while USPS Ground Advantage commercial rates under Notice 123 effective July 12, 2026 run $6.93 to $8.40 for an 8 oz 1-bottle order depending on zone. We checked those numbers because a payout that clears at zone 1 can break at zone 8.

Payments risk is not a back-office issue; it changes what an advertiser can afford to pay you. Visa's VAMP, Visa Acquirer Monitoring Program, counts fraud plus disputes over settled card-absent transactions, and Visa's fact sheet says the VAMP Ratio is "Count of Fraud (TC40) + Disputes (TC15) / Count of Settled Transactions (TC05)." Under the 2026 threshold, a U.S. merchant can be excessive at 1.50%, which leaves little room for trial confusion.

• A cheap capsule SKU can still lose money if refund and dispute rates rise after billing descriptor confusion.
• A high payout can be rational when the advertiser owns manufacturing, has low return rates, and captures rebills cleanly.
• A low payout can still be too high if the offer relies on negative-option billing, meaning recurring charges after an initial signup, without clear cancellation paths.

how do you compare two offers honestly?

You compare two offers by normalizing them to approved profit per 1,000 clicks, not by sorting the network dashboard by payout. For your own decision, use the same traffic source, same daypart, same device mix, and same exclusion rules; otherwise you are comparing audience quality, not offer economics.

Our working sheet starts with EPC, earnings per click, then breaks it into click cost, conversion rate, approval rate, holdback, refund exposure, and payment timing. A $120 payout with a 20% approval haircut and 30-day net terms can be worse than a $70 payout that pays weekly with low rejects. That point is dull until cash is tight; then it becomes the whole business.

The claim most buyers underprice is that a lower payout is often the better offer. Visa says VAMP "excludes disputes resolved through pre-dispute solutions," which means a merchant with Verifi, RDR, clear descriptors, and fast support can buy more stable traffic than a merchant that merely bids higher. The higher number can be the liquidation price for risk the advertiser is handing to you through caps, clawbacks, or sudden pauses.

If the offer sits near medical-adjacent demand, compare it against real supply and compliance pressure, not only funnel copy. The same buyer researching weight loss programs that offer glp 1 should ask whether the offer can legally make the claims that drive the click, because payment and platform risk usually arrives after the first profitable day.

what does the network keep?

The network keeps the spread between what the advertiser pays and what it passes to you, plus any operational advantage it has in tracking, placement, payment terms, or risk allocation. That spread is not automatically abusive; a network that fronts cash, filters affiliates, handles compliance reviews, and absorbs advertiser delay has a real cost base.

The exact spread is usually private, and we could not verify a published standard commission percentage for PSA-style direct-response affiliate networks; advertiser insertion orders, network payout logs, or audited platform records would settle it. In practice, your useful question is whether the network's behavior matches a partner taking margin or a broker hiding economics.

Ask for the event definition in writing. If the offer is a sale, define sale. If it is a trial, define whether shipping-only transactions count. If it is rev share, define gross revenue, net revenue, refund timing, reserve treatment, and rebill attribution. The affiliate who asks those questions before scaling usually gets cleaner answers than the one asking after a scrub.

If the traffic relies on cloaked claims or mismatched landing pages, the spread discussion is already secondary; the economics are being built on policy evasion. We keep a separate reference on where cloakers come from because that behavior changes platform risk before it changes payout math.

when does the payout arrive, and on what terms?

The payout arrives on the network's payment cycle only after tracking, advertiser approval, fraud checks, refund windows, and any reserve terms clear. Net-7, net-15, and weekly wires can mean very different cash outcomes if the offer has a delayed validation window or rolling holdback.

Reserves matter because high-risk processing can hold cash behind the advertiser before the advertiser funds the network. Typical high-risk merchant reserves in the fact pack run 5%-15% of processing volume held for 90-180 days, with nutraceuticals named among the verticals facing higher demands. If the advertiser's processor tightens terms, the affiliate payout can tighten next.

Card rules also affect timing. Visa's VAMP took effect April 1, 2025 and consolidated five prior fraud and dispute programs into one global acquirer program; Visa described it as "collapsing 38 separate remediation processes into one." Mastercard ECM, Excessive Chargeback Merchant, uses a lagged ratio: this month's Mastercard chargebacks divided by last month's Mastercard sales.

Your cash plan should assume the offer can pause before your test data feels complete.

• Ask whether the first payment requires manual review, minimum balance, tax forms, or advertiser clearance.
• Ask whether refunds and chargebacks create future deductions or immediate negative balance.
• Ask whether wire fees, currency conversion, or payment processor fees are deducted from your payout.

what does a bad offer look like on paper?

A bad offer looks good in the headline payout and bad in the definitions. The danger signs are vague conversion events, hidden approval rules, trial billing that depends on confusion, unsupported health claims, no written chargeback policy, weak fulfillment evidence, and a network contact who answers specific questions with urgency instead of numbers.

The paper trail matters because regulators and processors care about the promise, not the affiliate's intent. ROSCA, 15 U.S.C. 8403, requires clear material terms before billing information, express informed consent before charging, and simple mechanisms to stop recurring charges. California, New York, and Colorado add their own automatic-renewal requirements in the fact pack, so a trial-to-subscription offer has legal exposure even before Meta or Google review it.

Stripe's restricted-businesses list prohibits unsafe pseudo-pharmaceuticals and nutraceuticals or those making harmful claims, and separately prohibits negative-option subscription clubs with unclear or hidden pricing terms. That does not mean every supplement offer is unworkable. It means you should read the checkout, descriptor, cancellation flow, and claims page before you read the payout.

If the pitch wanders into peptides, semaglutide adjacency, or prescription-style claims, compare it with the real supply chain questions behind best peptides supplier and who manufactures semaglutide. The more the ad copy borrows pharmaceutical demand, the less useful a generic payout number becomes.

which numbers does the advertiser control?

The advertiser controls the numbers closest to the offer: price, AOV, average order value, COGS, cost of goods sold, refund handling, support speed, descriptor clarity, recurring billing design, and how much of the economics it shares as payout. You control traffic quality and pre-sell honesty, but the advertiser controls whether the back end survives your volume.

Some controls are operational. FDA says "the agency does not approve manufacturing facilities independently," and also says "FDA does not have the authority to approve dietary supplements before they are marketed." So an advertiser cannot turn FDA registration into product approval, and you should treat that language as a claims risk signal if it appears on a VSL, video sales letter.

Other controls are media-facing. A buyer using an ad library tool can see whether the advertiser rotates claims, angles, domains, and disclaimers faster than normal testing would require. That pattern does not prove bad faith, but it tells you the payout may be compensating affiliates for fragile compliance.

The advertiser also controls disclosure quality at checkout. FDA's supplement label guide requires the statement of identity, net quantity, Supplement Facts panel, ingredient list, and name and place of business on the container; 21 CFR 101.93 requires a structure/function disclaimer when applicable. Those rules do not set your payout, but they shape the risk that decides whether the payout remains payable after scale.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For educational pages, the supporting references should help readers verify search, crawlability, and public ad research context, especially Google helpful content guidance, Google SEO link best practices, and Meta Ad Library. Daily Intel then adds the direct-response interpretation layer so the page explains what the signal means for actual affiliate research decisions.

For deeper evaluation, continue through Fusion Peptide Affiliate Program: The Practical Version, Nad Supplement Affiliate Program: A Reference for Operators, How to Find Clickbank Id, Clickbank Order Lookup: The Practical Version, What is a VSL?, and UTM parameter decoding guide. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.